CEO total reported compensation of $6,617,979 is reasonable for a commercial-stage biopharmaceutical company of TARS's size and stage, and the pay mix is heavily weighted toward variable compensation — base salary of $735,000 represents only about 11% of total compensation, with the remainder in performance-linked equity and cash bonuses, well within the policy's requirement that fixed pay not exceed 40% of the total. The annual cash incentive was paid at 108% of target, supported by verifiable corporate goals including a 150% increase in net product sales from $180 million to $451 million, and the new performance stock award program is tied to three-year strategic milestones with a rigorous measurement period through 2027, demonstrating meaningful performance conditions rather than guaranteed payouts. The company maintains a clawback policy, double-trigger change-in-control arrangements, no tax gross-ups, and no repricing of underwater options — all consistent with strong pay governance practices.

Non-audit fees (tax services of $91,551) represent only about 3.9% of audit fees ($2,325,500), well below the 50% threshold that would raise independence concerns; auditor tenure is not disclosed in the proxy so the tenure trigger cannot be applied; no material restatements were identified; and Ernst & Young is a Big 4 firm appropriate for a $2.6 billion market-cap company.